Toxicology

Arrowhead Pharmaceuticals Reports Fiscal 2023 Year End Results

Retrieved on: 
Wednesday, November 29, 2023
Oncology, Health, Genetics, General Health, Pharmaceutical, Cardiology, Biotechnology, Webcast, Hypertriglyceridemia, GLP, Johnson & Johnson, Janssen Pharmaceuticals, Toxicology, International, RNA interference, Heart, AHA, GSK plc, Cholesterol, PIN, ERS, Patient, Cleveland Clinic, European Respiratory Society, Idiopathic pulmonary fibrosis, American Heart Association, GSK, MD, Janssen, Doctor of Philosophy, ANGPTL3, Triglyceride, Pharmaceutical industry, Medical device, Arrowhead, Medicine, APOC3

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal year ended September 30, 2023.

Key Points: 
  • Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal year ended September 30, 2023.
  • The company is hosting a conference call today, November 29, 2023, at 4:30 p.m.
  • ET to discuss the results.
  • JNJ-3989 (formerly ARO-HBV) was initially in-licensed by Janssen from Arrowhead in 2018

Philip Morris International to Present at 2023 Morgan Stanley Global Consumer & Retail Conference

Retrieved on: 
Tuesday, November 28, 2023
Tobacco, Retail, Smoke, Sale, ZYN, Fireside chats, IQOS, Research, NYSE, PMI, Food, Fireside, Toxicology, Conference, Philip Morris International, Life

Philip Morris International Inc. (PMI) (NYSE: PM)’s Chief Financial Officer, Emmanuel Babeau, will hold a Fireside Chat Q&A session at the 2023 Morgan Stanley Global Consumer & Retail Conference on Tuesday, December 5, 2023, at 09:30 a.m.

Key Points: 
  • Philip Morris International Inc. (PMI) (NYSE: PM)’s Chief Financial Officer, Emmanuel Babeau, will hold a Fireside Chat Q&A session at the 2023 Morgan Stanley Global Consumer & Retail Conference on Tuesday, December 5, 2023, at 09:30 a.m.
  • The webcast replay will be available at the same link until Friday, January 5, 2024.
  • Philip Morris International (PMI) is a leading international tobacco company working to deliver a smoke-free future and evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector.
  • In November 2022, PMI acquired Swedish Match – a leader in oral nicotine delivery – creating a global smoke-free champion led by the companies’ IQOS and ZYN brands.

Travis Parman Joins Philip Morris International as Vice President, Chief Communications Officer, U.S.

Retrieved on: 
Monday, November 27, 2023
Tobacco, Retail, Smoke, Sale, ZYN, Spokesperson, IQOS, Research, NYSE, PMI, Food, Toxicology, Ally Financial, General Motors, Nicotine, Appharvest, PulteGroup, Philip Morris International, University, Syracuse University, Life

Philip Morris International Inc. (PMI) (NYSE: PM) announced today that it has appointed Travis Parman Vice President, Chief Communications Officer, U.S. Parman will lead communications for PMI’s U.S. business as the company progresses toward its goal of delivering a smoke-free future for adults who currently smoke and would otherwise not quit.

Key Points: 
  • Philip Morris International Inc. (PMI) (NYSE: PM) announced today that it has appointed Travis Parman Vice President, Chief Communications Officer, U.S. Parman will lead communications for PMI’s U.S. business as the company progresses toward its goal of delivering a smoke-free future for adults who currently smoke and would otherwise not quit.
  • “We are thrilled that Travis is joining us in our bold ambition to deliver a smoke-free future in the United States.
  • He previously held multiple roles with the Renault-Nissan-Mitsubishi Alliance in Paris, Nashville, and Yokohama, Japan—most recently as VP, International Communications and Global Engagement.
  • Parman holds a master’s degree in communications management from the Newhouse School of Public Communications at Syracuse University and a bachelor’s degree in communications from the University of Tennessee.

Enveric Biosciences Announces Manuscript Describing the Development of Lead Product Candidate, EB-373, to be Featured on the Cover of the Journal of Medicinal Chemistry

Retrieved on: 
Monday, November 27, 2023
Mental Health, Health, Other Science, Research, Science, Pharmaceutical, Biotechnology, Psilocybin, Medicinal chemistry, Absorption, Depression, American Chemical Society, Prodrug, Toxicology, ACS, Addiction, Journal, Therapy, Anxiety, Journal of Medicinal Chemistry, Pharmaceutical industry

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced a research article describing the development of lead therapeutic candidate, EB-373, a novel psilocin prodrug, will be published on the cover of the Journal of Medicinal Chemistry, a peer-reviewed journal published by the American Chemical Society (ACS).

Key Points: 
  • Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced a research article describing the development of lead therapeutic candidate, EB-373, a novel psilocin prodrug, will be published on the cover of the Journal of Medicinal Chemistry, a peer-reviewed journal published by the American Chemical Society (ACS).
  • The modifications made in the generation of the library of compounds offer the potential to reduce the duration of the psychedelic experience generated by psilocybin, while maintaining the long-term mental health benefits of psilocin.
  • “The publication in the Journal of Medicinal Chemistry, notably as the issue’s cover article, is a major step in validating the proficiency of Enveric’s innovation engine by demonstrating the comprehensive processes employed to rapidly generate and screen a large library of novel psilocin compounds,” said Joseph Tucker, Ph.D., Director and CEO of Enveric.
  • The company expects to complete all enabling preclinical studies by the end of 2023.

Philip Morris International Inc. Presents at Chief Executives For Corporate Purpose (CECP) 2023 CEO Investor Forum

Retrieved on: 
Tuesday, November 14, 2023
Tobacco, Retail, Professional Services, Environmental, Social and Governance (ESG), Smoke, Sale, Webcast, ZYN, IQOS, Research, NYSE, PMI, Food, TCFD, Toxicology, Climate change mitigation, Q&A, CECP, Philip Morris International, Life, Smoking

Philip Morris International Inc.’s (NYSE: PM) Chief Executive Officer, Jacek Olczak, presents today at the Chief Executives For Corporate Purpose (CECP) 2023 CEO Investor Forum in New York.

Key Points: 
  • Philip Morris International Inc.’s (NYSE: PM) Chief Executive Officer, Jacek Olczak, presents today at the Chief Executives For Corporate Purpose (CECP) 2023 CEO Investor Forum in New York.
  • The presentation will focus on how PMI has embedded sustainability across the company, as well as its sustainability strategy, performance, and progress.
  • PMI’s presentation will follow CECP’s Integrated Long-Term Plan framework to communicate its sustainable value creation strategy, strong performance, and key forward-looking metrics.
  • In addition, as this year’s CEO Investor Forum will be focused on Climate Action, PMI will also highlight its low-carbon transition plan and overall approach to managing its environmental impacts.

Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2024

Retrieved on: 
Monday, November 13, 2023
Defense, Health, FDA, Infectious Diseases, Pharmaceutical, Biotechnology, Contracts, NDA, Food and Drug Administration, Research, Bachelor of Science, Engineering, Food, Therapy, Infection, Technology transfer, Toxicology, Indian stock exchange, IND, Bank statement, Government, Patient, Strategic planning, Marketing, International Accounting Standards Board, New Drug Application, Investigational New Drug, USAFA, MBA, Partnership, CMC, TSX, Pharming, Drug development, Patent, Non-governmental organization, Pharmaceutical industry, Management, Cryptocurrency

Appili Therapeutics Inc. (TSX:APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense products, today announced its financial and operational results for the second quarter of its fiscal year 2024, which ended on September 30, 2023.

Key Points: 
  • Appili Therapeutics Inc. (TSX:APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense products, today announced its financial and operational results for the second quarter of its fiscal year 2024, which ended on September 30, 2023.
  • At Appili, we are proud of our strong government partnerships which enable us to advance this biodefense program towards an Investigational New Drug (“IND”).”
    The Company has made significant operational progress during this quarter.
  • Appili expects to receive additional milestone payments and royalties from its partner, Saptalis Pharmaceuticals (“Saptalis”) based on this FDA approval and Saptalis’ commercialization.
  • During our second fiscal quarter, Appili progressed early-stage development activities and regulatory activities.

Avstera Therapeutics Announces FDA Clearance of IND Application for AVS100, a Novel Highly Selective HDAC6 Inhibitor Targeting Solid Tumors

Retrieved on: 
Monday, December 18, 2023
Georgetown University, Tumor-associated macrophage, AMES, Research, GLP, Safety, Therapy, Incidence, RECIST, Toxicology, IND, Risk, Macrophage, Patient, FIH, PFS, MD Anderson Cancer Center, U.S. FDA, FDA, Pembrolizumab, Animal, ICB, SAB, Pharmacokinetics, Marketing, Investigational New Drug, FAAAS, Progression-free survival, ORR, MD, Cancer, MTD, Phase, Doctor of Philosophy, HDAC6, Biomarker, Infrared spectroscopy correlation table, Immunotherapy, Coronavirus Scientific Advisory Board, Neoplasm, Rat, Dog, Government, Pharmaceutical industry, Medicine

AVS100 is a novel, orally bioavailable selective HDAC6i targeting locally advanced or metastatic solid tumors, including in combination with pembrolizumab.

Key Points: 
  • AVS100 is a novel, orally bioavailable selective HDAC6i targeting locally advanced or metastatic solid tumors, including in combination with pembrolizumab.
  • "The FDA clearance of our IND for AVS100 marks an amazing step for our company towards the fulfillment of our mission.
  • "FDA clearance of our IND for AVS100 represents a significant milestone for Avstera's mission in providing state of the art oncological agents to tackle solid tumors.
  • Undoubtedly, the IND approval of AVS100 selective HDAC6 inhibitor will open new opportunities to potentially enhance response rates for patients."

Forget Cool Cats -- Dogs are the Real Potheads

Retrieved on: 
Wednesday, December 13, 2023
Pet, Daylily, Cat, Caustic ingestion, Plant, Poison, Toxicology, Kidney, Kidney failure, Dog, Orient, Flower, Poisoning, Pollen, Asiatic, Prognosis, Veterinarian, Water, Common, Lilium, Floral industry

MINNEAPOLIS, Dec. 13, 2023 /PRNewswire/ -- According to case data released by Pet Poison Helpline, marijuana is on this year's Top 10 Pet Poisons list for dogs, while cats don't seem to be too interested in sampling the jazz cabbage. Chocolate, however, is a toxin that has cross-over appeal to both species.

Key Points: 
  • If you live with cats, it is critical to know which lilies are toxic to your feline friend.
  • The most dangerous and potentially fatal lilies for cats are "true lilies" or those in the genus Lilium.
  • Additionally, daylilies (Hemerocallis), although not a true lily, may also cause kidney failure in cats.
  • Dogs may experience minor gastrointestinal upset after ingestion of these lilies but do not appear to develop kidney damage.

Innocan Pharma Announces Expert Team for LPT CBD Application to United States Food and Drug Administration

Retrieved on: 
Tuesday, December 12, 2023
Drug development, FSE, Emeritus, Research, DABT, Chronic pain, CSE, Entrepreneurship, Veterans Health Administration, CBD, Therapy, LPT, Toxicology, Book, Patient, Analgesic, FDA, Biology, Pharmacology, Caregiver, MD, Drug discovery, Abstract, University, Thermodynamics, The Co Founder, Doctor of Philosophy, Commendation, Publication, Partnership, Pharmaceutical industry, Pharmacy

The team is comprised of accomplished drug development and drug approval experts, with specific a experience in pharmacology, toxicology, clinical trials, and successful interaction with the FDA.

Key Points: 
  • The team is comprised of accomplished drug development and drug approval experts, with specific a experience in pharmacology, toxicology, clinical trials, and successful interaction with the FDA.
  • Dr. Robert B. Raffa, PhD, is Adjunct Professor at the University of Arizona College of Pharmacy and Professor Emeritus at Temple University School of Pharmacy.
  • Innocan CEO, Iris Bincovich, stated: "At Innocan, we continue to develop our liposomal CBD platform to play a role in effectively combating various diseases in the future.
  • We are excited to work with such leading experts to help Innocan Pharma achieve our gools and move the company forward with the FDA."

Canine Magician Makes Salted Dough Christmas Ornaments Disappear

Retrieved on: 
Wednesday, December 6, 2023
Vomiting, Pet, Hypernatremia, Toxicology, Risk, Thirst, Patient, Animal, Poisoning, Blood, Seizure, Water, Christmas, Drinking, Central nervous system, Lethargy, Nursing, Veterinary medicine, Medical imaging

BALTIMORE, Dec. 6, 2023 /PRNewswire/ -- Mary Mueller and her husband Paul Benson were enjoying a family day of baking after Christmas last year, making salted dough Christmas ornaments with their grandkids' handprints in them that would be tucked away for next year's tree. The holiday works of art were cooling on the counter when Mary noticed they had vanished.

Key Points: 
  • BALTIMORE, Dec. 6, 2023 /PRNewswire/ -- Mary Mueller and her husband Paul Benson were enjoying a family day of baking after Christmas last year, making salted dough Christmas ornaments with their grandkids' handprints in them that would be tucked away for next year's tree.
  • "It was about 6 p.m. when we noticed the ornaments were missing and we knew our dog Shandy was the only one who could have taken them," explained Mary.
  • "At first, we weren't too concerned but then Shandy became very thirsty and started drinking large amounts of water.
  • The playful pooch from Hunt Valley, Maryland, had taken their son's medication bottle into the back yard, chewed off the top, and ingested the pills.